GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection

Authors :: Vladimir Chulanov
Sandra Ciesek
Maura Dandri
Ulf Dittmer
Tatyana Stepanova
Stephan Urban
Heiner Wedemeyer
Jürgen Burhenne
Birgit Bremer
A. Alexandrov
Pavel O. Bogomolov
Natalia Voronkova
Walter-Emil Haefeli
Katrin Schöneweis
Lena Allweiss
Source :: Journal of Hepatology. 70:e81
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: medicine.medical_specialty
Hepatology
business.industry
Myrcludex B
Alpha (ethology)
Phases of clinical research
Gastroenterology
chemistry.chemical_compound
Peg interferon
chemistry
Internal medicine
medicine
In patient
Open label
business
Co infection

Full Text Access

Tools